|
|
Redefining Success for VAP: 360° Approach
|
Release Date: Monday, June 8, 2009
Credit Expiration Date: Tuesday, June 8, 2010
|
Credit Hours
Pharmacist CPE: 1.25 (0.125 CEUs)
|
|
Activity Type
Application-Based
|
Activity Overview
This online activity is based on the proceedings of a continuing education symposium held on
December 9, 2008, during the 43rd ASHP Midyear Clinical Meeting and Exhibition in Orlando, Florida.
This educational activity consists of three learning modules.
- In the introduction “Defining Success for VAP”, Dr. Nicolau discusses the burden of ventilator-associated
pneumonia and defines what constitutes success when a ventilator-associated pneumonia episode does
occur. Dr. Nicolau then introduces a typical case of ventilator-associated pneumonia and asks clinically
important questions that lead into the next learning module.
- Scientific Evidence addresses the challenges introduced by Dr. Nicolau. The most current data are
presented on etiology, resistance, appropriate therapy, PK/PD principles, and prevention of ventilator-associated
pneumonia. Please note that scientific evidence is supplemented with commentary by Dr. Burgess and Dr. Rodvold.
You can listen to the faculty commentary by clicking on the audio buttons. Please note that some pages are long
and you may need to scroll to view the complete information.
- Case Study learning module is designed to apply scientific evidence in practice setting. Throughout this Case
Study about a patient with ventilator-associated pneumonia questions are posed. Please take a moment to think
about what you would do. You will have the opportunity to compare your approach to that of the faculty by
listening to the Faculty Response.
|
Educational Overview
Among nosocomial infections, hospital-acquired pneumonia (including ventilator-associated pneumonia) is
the leading cause of death associated with substantial healthcare costs in US hospitals. Of serious
concern are bacterial resistance and inappropriate antimicrobial management, which lead to compromised
clinical outcomes. Early appropriate therapy is critical in (a) ensuring clinical success, (b) reducing
the risk of resistance development, and (c) improving healthcare utilization—the 3 parameters of success
of any management strategy. In this context, optimized dosing of antimicrobials, shortened duration of
therapy, and de-escalation have proven to be successful strategies.
As equal partners in the healthcare team, pharmacists are responsible for appropriately and successfully
managing these infections. Their increased responsibility in today’s healthcare environment has made
knowledge of the latest scientific evidence pertaining to successful management strategies an imperative.
|
Target Audience
This activity has been developed for pharmacists who are responsible for the management of serious
infections in hospitalized patients.
|
Purpose Statement
The purpose of this activity is to educate pharmacists managing serious hospital infections on appropriate
antimicrobial use to curb resistance development and improve resource utilization. With this knowledge, pharmacists
will be able to fulfill an expanded role within the healthcare team.
|
Learning Objectives
At the conclusion of this activity, participant should be able to
- Identify therapeutic strategies that minimize the risk of resistance development during treatment of ventilator-associated pneumonia.
- Recognize the importance of improving resource utilization in hospitals when treating serious infections.
- Discuss the role of clinical pharmacists in the overall management of patients with ventilator-associated pneumonia.
|
Faculty
David P. Nicolau, PharmD, FCCP, FIDSA
Director, Center for Anti-Infective Research and Development
Hartford Hospital
Hartford, CT
David S. Burgess, PharmD, FCCP
Clinical Professor of Pharmacy and Medicine
University of Texas at Austin, Austin, TX
University of Texas Health Science Center at San Antonio
San Antonio, TX
Keith A. Rodvold, PharmD, FCCP, FIDSA
Professor of Pharmacy Practice and Medicine
Colleges of Pharmacy and Medicine
University of Illinois at Chicago
Chicago, IL
|
Accreditation
Pharmacists
Accreditation
Statement: Center for Independent Healthcare Education (Center) is accredited by the
Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Credit Designation: Center has assigned 1.25 contact hours (0.125 CEUs) of continuing pharmacy
education credit for participation in this activity.
ACPE Universal Activity Number: 473-999-09-010-H01-P
Estimated time to complete activity: 1.25 hours
For questions regarding the accreditation of this activity, please contact Center at info@jointsponsor.com.
|
Method of Participation and Instruction for Credit
- Review the entire CME/CE information including target audience, learning objectives, and disclosures.
- Review all learning modules in their entirety.
- Print and complete the Post Test, Evaluation, and Credit Application form.
- Mail the completed Post Test, Evaluation, and Credit Application form to Vemco MedEd, 245 US Highway 22, Suite 304, Bridgewater, NJ 08807 Or Fax to (908) 450-3300.
Documentation of credit will be mailed within 4 weeks of receipt of the completed Post Test, Evaluation, and Credit Application form.
|
Disclosure of Conflict of Interest
Center for Independent Healthcare Education requires faculty, planners, and others who are in a
position to control the content of continuing education activities to disclose to the audience
any real or apparent conflict of interest related to the activity. All identified conflicts of
interest are reviewed to ensure fair balance, objectivity, and scientific rigor in all activities.
The faculty is further required to disclose discussion of off-label uses in their presentations.
|
Disclosures
Faculty
David P. Nicolau, PharmD, FCCP, FIDSA
Grant/research support and speakers bureaus: AstraZeneca, Johnson & Johnson, Cubist, Wyeth, Merck, Pfizer, and Schering-Plough
David S. Burgess, PharmD, FCCP
Advisory committees and speakers bureaus: Forest Pharmaceuticals and Wyeth
Grant/research support: AstraZeneca and Wyeth
Keith A. Rodvold, PharmD, FCCP, FIDSA
Consultant: Johnson & Johnson, Astellas, GlaxoSmithKline, Theravance, Targanta, and Intranasal Therapeutics
Advisory committees: Johnson & Johnson, Targanta, Baxter, and Pfizer
Speakers bureaus: Johnson & Johnson, Wyeth, Pfizer, and Schering-Plough
Planning Committee Members
Employees of Center for Independent Healthcare Education and Vemco MedEd have no relevant financial relationships to disclose.
Disclosure of Off-label Use
During this activity, the following off-label uses of antimicrobial agents are
discussed: doripenem (for the treatment of ventilator-associated pneumonia), ertapenem
(administered via a 3-hour infusion), gentamicin (dosed once-daily), piperacillin/tazobactam
(administered via continuous infusion), and tigecycline (for the treatment of ventilator-associated pneumonia).
|
Joint Sponsorship
This activity is jointly sponsored by Center for Independent Healthcare Education and Vemco MedEd.
|
Commercial Support
This activity is supported by an educational grant from Ortho-McNeil, Inc., administered by
Ortho-McNeil Janssen Scientific Affairs, LLC.
|
Fee
There is no fee to participate in this educational activity.
|
Hardware/Software Requirements
Web Browser
Internet Explorer or Mozilla
Note: Please disable any “pop-up blocker” features.
Software
Flash Player to view the presentations
Adobe Acrobat Reader version 4 or above to view PDF files (If you do not have Acrobat Reader, you can download it
for free from http://get.adobe.com/reader)
Connection Speed
Cable, DSL, or better of at least 300 kbps
Hardware
PC or Apple to view the presentations
Audio Speakers
System Check
Please e-mail any questions or concerns to info@vemcomeded.com.
|
Copyright Statement
Copyright © 2009 Vemco MedEd, LLC. All Rights Reserved.
Permission for accreditation use granted to Center for Independent Healthcare Education.
|
Disclaimer
The opinions expressed in this educational activity are those of the faculty and do not reflect
the views of Center for Independent Healthcare Education (Center) and Vemco MedEd. This educational
activity may discuss off-label and/or investigational uses and dosages for therapeutic
products/procedures that have not been approved by the United States Food and Drug
Administration (FDA). Center and Vemco MedEd do not recommend the use of any product/procedure
outside of the labeled indications. A qualified healthcare professional should be consulted
before using any therapeutic product/procedure discussed. Learners should verify all information
and data before treating patients or employing any therapies described in this continuing
education activity. Please refer to the official prescribing information for each product/procedure
for approved indication, contraindications, and warnings.
|
Privacy Policy
http://www.vemcomeded.com/privacy.asp
|
Contact Information
For questions regarding the accreditation of this activity, please contact Center for Independent Healthcare
Education at info@jointsponsor.com
|
Start Activity
|
By clicking on the icon to begin the educational activity, I acknowledge that I have read the entire CPE information.
|
|
|
|
|
|